Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02358967 · ClinicalTrials.gov registry record · NA

Palm Tocotrienols in Chronic Hemodialysis (USA)

A NA study of Chronic Kidney Disease and End Stage Renal Disease, sponsored by Wayne State University.

Completed
Registry status
NA
Development phase
280
Enrollment target
1
Study location

NCT02358967 is a NA study of Chronic Kidney Disease and End Stage Renal Disease that has completed, run by Wayne State University. The registered enrollment target is 280 participants, below the 3,204-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02358967, a NA study of Chronic Kidney Disease and End Stage Renal Disease, has completed, sponsored by Wayne State University.

COMPLETED
Registry status
NA
Development phase
280 participants
Enrollment target
1
Study location

Study Summary

Patients undergoing chronic hemodialysis are at increased risk for cardiovascular disease, attributed in part to increased oxidative stress, inflammation and dyslipidemia. Intervention with a naturally occurring dietary supplement may improve certain biomarkers of inflammation and oxidative stress and improve the lipid profile.

Interventions

  • DIETARY_SUPPLEMENT Placebo
  • DIETARY_SUPPLEMENT TRF (Tocotrienol-rich-fraction)

Study Locations (1)

Michigan

  • Wayne State University - Detroit

Trial Details

FieldValue
Enrollment Target 280 participants
Start Date 2017-06-15
Est. Completion 2020-08-31
Phase NA

Sponsor

Wayne State University

163 total trials

What the Registry Record Tells You About NCT02358967

The ClinicalTrials.gov registry entry for NCT02358967 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 280 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,204-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (91% lower). The listed sponsor is Wayne State University, which has 163 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Chronic Kidney Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02358967 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.

Frequently Asked Questions

What is clinical trial NCT02358967 about?

NCT02358967 is a clinical study titled "Palm Tocotrienols in Chronic Hemodialysis (USA)". Patients undergoing chronic hemodialysis are at increased risk for cardiovascular disease, attributed in part to increased oxidative stress, inflammation and dyslipidemia. Intervention with a naturally occurring dietary supplement may improve certain biomarkers of inflammation and oxidative stress a...

What is the current status of trial NCT02358967?

This trial is currently completed. It is a NA study. The enrollment target is 280 participants. The study started on 2017-06-15. Estimated completion is 2020-08-31.

What conditions does trial NCT02358967 study?

This clinical trial studies the following conditions: Chronic Kidney Disease, End Stage Renal Disease.

What interventions are being tested in trial NCT02358967?

The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), TRF (Tocotrienol-rich-fraction) (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT02358967?

This trial is sponsored by Wayne State University, which has 163 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02358967 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Kidney Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.